- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
- Media
- Partners
- Contact Us
Dr. Reddy's in the news
-
Dr. Reddy's bags Sustainability 4.0 Awards
Click Here for the Complete Story [PDF Format] -
Fermenta Biotech licenses its proprietaryenzymatic technology for manufacturingMolnupiravir to Aurigene Pharma
Click Here for the Complete Story [PDF Format] -
Fermenta Biotech Limited exclusively licenses its proprietary enzymatic technology for manufacturing Molnupiravir to Aurigene Pharmaceutical Services Ltd
Click Here for the Complete Story [PDF Format] -
Fermenta has signed a Definitive Agreement with Aurigene for Molnupiravir
Click Here for the Complete Story [PDF Format] -
Fermenta has signed a Definitive Agreement with Aurigene, a stepdown subsidiary of Dr. Reddy's Limited
Click Here for the Complete Story [PDF Format] -
Innovation in R&D Top Focus
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Labs bags Frost & Sullivan and TERI’s Sustainability 4.0 Awards 2021
Click Here for the Complete Story [PDF Format] -
Budget 2022-23 Wishlist
Click Here for the Complete Story [PDF Format] -
India to become hub for Covid-19 antiviral generic drugs: Fitch
Click Here for the Complete Story [PDF Format] -
Raising their generics game
Click Here for the Complete Story [PDF Format] -
University of Hyderabad, Dr Reddy's to build cold chain solutions for pharma industry
Click Here for the Complete Story [PDF Format] -
Merck's Anti - Covid Pill 'Molflu' 5-Day Course To Cost ₹1,400 In India
Click Here for the Complete Story [PDF Format] -
Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment
Click Here for the Complete Story [PDF Format] -
Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment
Click Here for the Complete Story [PDF Format] -
Dr Reddy's to launch molnupiravir next week at ₹35 per capsule
Click Here for the Complete Story [PDF Format] -
India Inc sees investment boom, lines up capex plans
Click Here for the Complete Story [PDF Format] -
Predictions 2022
Click Here for the Complete Story [PDF Format]
